Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.
CONCLUSIONS: Treatment with dapagliflozin for six months significantly improved glycemic control and reduced body weight without reducing muscle mass in T2DM patients.
PMID: 29225209 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
More News: CT Scan | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Forxiga | Japan Health | Sodium | Thrombosis